Accuray Incorporated
$ 0.44
-0.79%
17 Apr - close price
- Market Cap 52,466,000 USD
- Current Price $ 0.44
- High / Low $ 0.46 / 0.43
- Stock P/E N/A
- Book Value 0.45
- EPS -0.31
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.70 %
- 52 Week High 2.10
- 52 Week Low 0.33
About
Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.
Analyst Target Price
$2.52
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-05 | 2025-08-13 | 2025-04-30 | 2025-02-05 | 2024-11-06 | 2024-08-14 | 2024-05-01 | 2024-01-31 | 2023-11-07 | 2023-08-09 | 2023-04-26 |
| Reported EPS | -0.1076 | -0.1392 | 0.01 | -0.01 | 0.02 | -0.04 | 0.03 | -0.06 | -0.1 | -0.03 | -0.03 | 0.01 |
| Estimated EPS | -0.11 | -0.06 | 0.02 | -0.04 | -0.04 | -0.06 | 0.03 | -0.01 | -0.05 | -0.05 | 0.01 | -0.01 |
| Surprise | 0.0024 | -0.0792 | -0.01 | 0.03 | 0.06 | 0.02 | 0 | -0.05 | -0.05 | 0.02 | -0.04 | 0.02 |
| Surprise Percentage | 2.1818% | -132% | -50% | 75% | 150% | 33.3333% | 0% | -500% | -100% | 40% | -400% | 200% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARAY
2026-04-17 10:09:37
TCW Group has reported a beneficial ownership of 11.5% in Accuray Inc. (ARAY), amounting to 15,467,952 shares, primarily through warrants. These warrants, issued on December 15, 2025, were part of amendments to a Financing Agreement and have exercise prices ranging from $0.01 to $1.50, expiring on December 15, 2032. The disclosure indicates that no separate consideration was paid for these warrants, and none have been exercised to date, with their purpose being to incentivize agreement to the financing amendments.
2026-04-12 18:09:42
The article displays the title "CapEx per share of Accuray Incorporated – LSE:0H8I" and indicates that the market is closed with no trades. It provides a structured view for financial information, news, community, technicals, forecasts, seasonals, bonds, and ETFs related to Accuray Incorporated on the London Stock Exchange.
2026-04-10 20:38:56
Accuray Inc.'s Senior Vice President and Chief Commercial Officer, Paul Michael Miele, has filed a Form 3, an initial statement of beneficial ownership of securities. This filing officially establishes Miele as a reporting insider for Accuray (ARAY) but does not indicate any specific share transactions or existing holdings. The Form 3 serves to publicly acknowledge new insiders and their initial ownership status, rather than reporting changes in ownership.
2026-04-09 09:16:27
Accuray Incorporated has announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead the company's global commercial organization, focusing on transformation, strengthening execution, and enhancing commercial performance. His extensive experience in medical technology, including a commercial turnaround at Johnson & Johnson MedTech, is expected to drive Accuray's long-term value creation and growth in systems and services sales.
2026-04-07 14:10:26
Accuray (ARAY) has amended its consulting agreement with Dedication Capital, an affiliate of director Steven F. Mayer, effective April 1, 2026. The amendment cuts the base consulting fee and minimum cash incentive amounts by 50% and accelerates equity vesting for 916,336 restricted shares and all performance stock awards. These changes, along with an extension of the consulting end date to October 31, 2026, and the vesting of an additional 333,004 restricted shares, are expected to save Accuray at least $362,500.
2026-04-07 13:10:26
Accuray Incorporated has amended its consulting agreement with Dedication Capital, LLC, reducing cash compensation and modifying equity vesting terms, expecting to save at least $362,500. This comes as the medical device company faces a significant debt burden and a recent stock decline, though it recently gained nearly 8%. The agreement extension and vesting changes are part of ongoing financial and corporate adjustments.
